CHU St Pierre (St Pierre)

Brussels 1000

1 studies enrolling now · 6 studies all time

What they study most

Crohn Disease, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Rheumatoid Arthritis, Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors — Completed